Location: The person in this role must reside in the Bay Area, California to support customers

Sartorius has an exciting opportunity for a dynamic, self-motivated, professional to help support our customers within the Northwest region for our Separation Technology products. In this remote position, the incumbent will play a key role as a trusted business partner to our customers. This is an exciting opportunity to join a global company known for a great culture, innovative products and stability. If interested, please read on.

The Field Application Specialist will be responsible for ensuring the successful application, implementation, qualification, and use of Sartorius’ Separation technologies portfolio by providing overall product expertise, application knowledge, and technical support throughout each step of the customer process. This role supports the Sales process through product positioning, presentations, demonstrations, and trials, primarily for customers in Northern California and at times the Pacific Northwest region.

What will accomplish

Support the Sales organization on existing products through product presentations, demonstrations, application studies, and products in close collaboration with product management through beta sites testing and demonstrations.
Support Sales in the customer process, URS analysis and technical response
Be responsible for the assigned product line (Separations) to support sales target achievement and grow market share in defined Region
Conduct product trials and demos to achieve intended results and create trial reports for customers, sales and application teams.
Support the Quality Department in the quality complaint process by troubleshooting and analyzing customer processes for better investigation and resolution.
Report on competitor product implementation & presence within the territory and feedback information to the Application Specialist Team and Management.

What will convince:

Bachelor's degree in biological engineering, biotechnology or other life sciences related field.
Demonstrate 3+ years of experience in process development, MSAT, bioprocessing in biotechnology, biopharmaceutical industry or CDMO environment or field experience in a similar role
Extensive experience in TFF, UF/DF, NFF, Viral Filtration and Clarification products with optimization and process scaling success.
Demonstrate the ability to present data, findings and recommendations to customers
Strong customer orientation with excellent communication and presentation skills
Team player, able to interact with people across different functions, while being comfortable working independently
Highly organized and capable of planning own schedule
Identification with our core values: Sustainability, Openness, Enjoyment
Occasional overnight travel will be required to support customers / sales, to attend organizational meetings and training will be required (~40%). This travel requirement is subject to change based on customer and internal business need.

What We Offer

As a growing global life science company, with our stock listed on the German DAX and TecDAX , Sartorius offers a wide range of benefits:
Personal and Professional Development: Mentoring, leadership programs, internal seminar offerings
Worklife Balance: Paid vacation, sick time, corporate holidays and community service day; as well as flexible work schedules
Making an Impact Right from the Start: Comprehensive onboarding, including a virtual online platform
Welcoming Culture: Mutual support, team spirit and international collaboration; communities on numerous topics such as “Coaching”, “Agile Working” and a “Businesswomen’s Network”
Health & Well Being: Wide selection of health and well-being support such as a variety of medical plans to choose from, dental, vision, EAP, and other wellness programs.
Intelligent Working Environment: Working in smart buildings with the latest technology and equipment.

Retirement Savings Plan: 401 k (with generous company match)
Flexible Spending: HSA, FSA (dependent care & healthcare spending), Transportation Commuter Account
Company Paid Benefits: Basic Life Insurance, AD&D, EAP, Family Planning & Women’s Health, Health Advocate
Additional/Optional: Supplemental Life Insurance (employee, spouse & dependents), Legal Services, LTD & STD, Critical Illness Insurance, Student Loan Tuition Refinance Service

Base compensation is $105,000 to $120,000 depending on experience and also includes a bonus and auto allowance.

Sartorius is an equal opportunity employer and will consider all qualified applicants for employment without regard to race, color, religion, sex, national origin, age, protected veteran status, disability or based on status in any other protected group of class.

Please view equal employment opportunity posters provided by OFCCP here.

E-Verify Participation Info

E-Verify Workers Rights

For Residents of California please review;

CA Privacy Notice for Employees

#LI-remote

Sartorius is part of the solution in the fight against cancer, dementia, and many other diseases. Our technologies help translate scientific discoveries into real-world medicine faster, so that new therapeutics can reach patients worldwide. We look for ambitious team players and creative minds, who want to contribute to this goal and advance their careers in a dynamic global environment. Join our global team and become part of the solution. We are looking forward to receiving your application.

We look forward to receiving your application.

www.sartorius.com/career

If you are a qualified individual with a disability or a disabled veteran and are unable or limited in your ability to use or access our website, you may request a reasonable accommodation to express interest in a specific opening. You can request reasonable accommodation by e-mail at [email protected]

Sartorius is an equal opportunity employer and will consider all qualified applicants for employment without regard to race, color, religion, sex, national origin, age, protected veteran status, or disability, or based on status in any other protected group of class.

About Sartorius

We look for ambitious team players and creative minds, who want to contribute to this goal and advance their careers in a dynamic global environment.

Join our global team and become part of the solution. We are looking forward to receiving your application.
www.sartorius.com/careers

About the company

Sartorius provides laboratory and bioprocessing equipment and services for the biopharmaceutical industry. Its two divisions, Bioprocess Solutions and Lab Products & Services, supply systems, consumables, and analytics used in biotech drug and vaccine development and production. It differentiates itself with a long history, an integrated portfolio, global support, and acquisitions like BioOutsource to offer end-to-end solutions. Its goal is to help biopharmaceutical companies develop and manufacture biotech products more reliably and at scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Get referred to Sartorius

See people who can refer or advise you

Simplify's Take

What believers are saying

H1 2026 operational sales rose 7.7%, and management reaffirmed full-year guidance.
May 2026 bond refinancing lowered funding pressure before the €650 million maturity.
ElevateBio pilot validation and September 2026 ordering support Eveo sales conversion in 2027.

What critics are saying

Tariff refunds and customer compensation cut 2026 revenue by up to €35 million.
Lab Products grew only 5.3% operationally in H1 2026, lagging Bioprocess Solutions.
Delayed advanced-therapy orders from two customers shift revenue into 2027, hurting execution confidence.

What makes Sartorius unique

Eveo launches March 16, 2026, integrating cell therapy manufacturing and QC in one system.
Bioprocess Solutions dominates with high-recurring consumables and switching costs across biologics manufacturing.
Stedim Biotech integration gives Sartorius tighter control over single-use bioprocessing and global customer relationships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Flexible Work Hours
Wellness Program
Professional Development Budget

Company News

Yahoo Finance

Jul 23rd, 2026

Sartorius reports 7.7% sales growth as bioprocess equipment stabilises

Sartorius reported solid first-half results, with constant-currency sales up 7.7% and underlying EBITDA rising 3.9% as margins improved to 30.3%. Management confirmed full-year guidance. Bioprocess Solutions led performance, growing 8.3% in constant currencies. Consumables drove growth, whilst equipment stabilised slightly. Chief executive Michael Grosse said demand for biologics remains robust, particularly in monoclonal antibody manufacturing. However, advanced-therapy orders from two customers were delayed and could shift revenue into 2027. Tariff refunds and accounting effects distorted reported results but did not change underlying business trends. The company booked €26 million in customer compensation related to tariffs. Operating cash flow and free cash flow both improved sharply in the first half.

AD HOC NEWS

May 15th, 2026

Sartorius completes full takeover of Stedim Biotech, delisting bioprocessing unit from Euronext Paris

Sartorius Stedim Biotech is set to be delisted from Euronext Paris following a squeeze-out by majority shareholder Sartorius Group. The voluntary tender offer and subsequent acquisition process, which began in early 2024, will transition the company from a separately traded stock into a fully integrated part of Sartorius Group. Headquartered in Aubagne, France, Sartorius Stedim Biotech develops bioprocessing equipment and single-use technologies for biopharmaceutical manufacturing. Its products include bioreactors, filtration systems and process automation tools used by pharmaceutical and biotech companies globally. North America represents a key market, with many US-based biopharma firms using its technologies. The company experienced normalised growth following pandemic-era demand surges, with customers working through elevated inventories accumulated during vaccine production. Despite short-term headwinds, long-term demand drivers remain supported by expanding biologics and advanced therapy pipelines.

wallstreet:online AG

May 6th, 2026

Sartorius completes $560M bond placement with 3.75% coupon to refinance existing debt

Sartorius has completed a €500 million bond placement via its Dutch subsidiary Sartorius Finance B.V. The five-year bond, targeted at institutional investors, was more than four times oversubscribed and carries a 3.75% annual coupon. The life science group will use the proceeds for general corporate purposes, including refinancing existing debt. This includes the redemption of a €650 million bond with a 4.25% interest rate due in autumn 2026. Sartorius has applied for admission to trading on the Euro MTF market of the Luxembourg Stock Exchange. Chief financial officer Florian Funck said the successful issuance strengthens the company's balanced debt maturity profile and long-term financing position, whilst demonstrating investor confidence in Sartorius' strategic direction.

Sartorius

May 6th, 2026

Sartorius completes placement of bond with a volume of 500 million euros

May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.

Associated Press

Mar 16th, 2026

Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.